Search Results

You are looking at 31 - 40 of 69 items for :

  • "bisphosphonates" x
Clear All
Full access

Deborah 26 * DO Wagner Nina 27 MD Dwyer Mary A. 28 * MS, CGC Sundar Hema 28 * PhD 1 2019 17 17 1 1 12 12 20 20 10.6004/jnccn.2019.0002 Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma Leng Siyang a MD, MS Chen

Full access

Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Michaela Liedtke, Thomas Martin, James Omel, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar

-typed. Because bisphosphonate therapy is a consideration in patients with MM, a baseline bone densitometry test may be recommended. Diagnostic Categories Based on the results of the clinical and laboratory evaluation discussed in prior sections

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff

metabolism during adjuvant breast cancer treatment . J Natl Cancer Inst 2005 ; 97 : 30 – 39 . 203 Hillner BE Ingle JN Chlebowski RT . American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns and Rashmi Kumar

; expected survival is ≥3 months. Patients should undergo a dental examination with preventive dentistry before starting this therapy. The bisphosphonates and denosumab are associated with a risk of development of osteonecrosis of the jaw (ONJ). Poor baseline

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff and Richard Zellars

breast cancer in bone to prevent bone fractures, bone pain requiring radiation therapy, spinal cord compression, and hypercalcemia (skeletal related events [SREs]). 279 – 281 The bisphosphonates zoledronic acid or pamidronate have been used for this

Full access

Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy

effects (eg, bisphosphonates for AI-induced osteoporosis) may have played a role in the state-to-state variations they found. Conclusions In 2006 and 2007, when AIs were much more expensive than tamoxifen, adjuvant endocrine therapy prescribing

Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar

. In such cases, the patient will need to be HLAtyped. Since bisphosphonate therapy is a consideration in patients with MM, a baseline bone densitometry test may be recommended. Diagnostic Categories Based on the results of the clinical and

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

with an increase in frequency of electrolyte abnormalities and osteonecrosis of the jaw; bisphosphonates are also associated with renal insufficiency. Conclusions The NCCN Guidelines for Breast Cancer represent a dynamic, evolving series of

Full access

Lee S. Schwartzberg and Sarah L. Blair

Breast Cancer Trialists' Collaborative Group (EBCTCG) Coleman R Powles T . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials . Lancet 2015 ; 386 : 1353 – 1361 . 15

Full access

James L. Mohler

2016 ; 387 : 1163 – 1177 . 18. Vale CL Burdett S Rydzewska LH . Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of